Pfizer Inc

NYSE: PFE
$29.27
-$0.40 (-1.3%)
Closing Price on October 17, 2024

PFE Articles

It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and even longer before profits can be considered.
Drugmaker Pfizer beat estimates on both the top and bottom lines for the first quarter, and shares rallied after the report.
24/7 Wall St. has put together a preview of Apple, Pfizer and other Dow companies scheduled to report their quarterly results this week.
The April 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.
Here is a slate of 15 companies that most retirees likely would want to own in their portfolio now, including AT&T, Boeing, Pfizer and Walmart.
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.
Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer.
According to Credit Suisse, Pfizer investors might be getting to make up some of that relative underperformance of late.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks. Many others saw sizable increases in their short interest.
Stock buybacks have come under more scrutiny by the public and politicians in recent years, but companies still aggressively are buying back shares of their own stock.
These five top stocks, all rated Buy at Merrill Lynch, come with outstanding dividends and have good growth prospects.
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.